0001209191-18-012730.txt : 20180222
0001209191-18-012730.hdr.sgml : 20180222
20180222194253
ACCESSION NUMBER: 0001209191-18-012730
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180220
FILED AS OF DATE: 20180222
DATE AS OF CHANGE: 20180222
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ciechanover Isaac E.
CENTRAL INDEX KEY: 0001612096
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36548
FILM NUMBER: 18634307
MAIL ADDRESS:
STREET 1: C/O ATARA BIOTHERAPEUTICS, INC.
STREET 2: 3260 BAYSHORE BOULEVARD
CITY: BRISBANE
STATE: CA
ZIP: 94005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Atara Biotherapeutics, Inc.
CENTRAL INDEX KEY: 0001604464
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 460920988
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 611 GATEWAY BLVD
STREET 2: SUITE 900
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-278-8930
MAIL ADDRESS:
STREET 1: 611 GATEWAY BLVD
STREET 2: SUITE 900
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-02-20
0
0001604464
Atara Biotherapeutics, Inc.
ATRA
0001612096
Ciechanover Isaac E.
611 GATEWAY BOULEVARD
SUITE 900
SOUTH SAN FRANCISCO
CA
94080
1
1
0
0
Chief Executive Officer
Common Stock
2018-02-20
4
S
0
8700
45.28
D
234178
I
See footnote
Common Stock
2018-02-21
4
S
0
1589
43.60
D
232589
I
See footnote
Common Stock
2018-02-21
4
S
0
2911
44.55
D
229678
I
See footnote
Common Stock
2018-02-22
4
S
0
1600
42.74
D
228078
I
See footnote
Common Stock
2018-02-22
4
S
0
1600
44.03
D
226478
I
See footnote
Common Stock
2018-02-22
4
S
0
1400
45.00
D
225078
I
See footnote
Common Stock
812613
D
Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $45.00 to $46.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $43.05 to $44.05. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $44.10 to $45.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $42.45 to $43.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $43.60 to $44.50. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $44.70 to $45.25. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
/s/ David Tucker, Attorney-in-Fact for Isaac E. Ciechanover
2018-02-22